JAZZ · available-data snapshot
Jazz Pharmaceuticals plc (JAZZ): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Jazz Pharmaceuticals plc (JAZZ); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for JAZZ?
We do not publish a fair value for Jazz Pharmaceuticals plc. What we can say from its filings and market data is below.
What is JAZZ's TickerWorth Score?
Scores higher than most companies we compare it with
Compared with Healthcare companies in US
Its strongest point: looks cheap on the numbers. Its weakest: balance sheet looks stretched.
our cash-flow model doesn't fit this business, so we won't award our top grade off the remaining lenses
- Value · 81 of 100
Cheaper than 81% of Healthcare companies in US
- Price vs worth · 100 of 100
- Quality · 84 of 100
More profitable than 84% of Healthcare companies in US
- Financial health · 44 of 100
Financially stronger than 44% of Healthcare companies in US
- Growth · 67 of 100
Growing faster than 67% of Healthcare companies in US
- Momentum · 58 of 100
Outperformed 58% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $207.69
- Market cap
- $13,
482, 108, 928 - 52-week high
- $266.38
- 52-week low
- $128.80
- Currency
- USD
- Exchange
- NasdaqGS
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Jazz Pharmaceuticals plc (JAZZ) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, JAZZ trades at a recent price of $207.69, a market capitalisation of about $13,482,108,928, sitting 57% of the way up its 52-week range ($128.80–$266.38), on the NasdaqGS.
The standard alternative to a DCF is relative valuation — comparing JAZZ's trading multiples against a sector benchmark. Here that gives P/E of 14.2× (cheaper than the peer median of 41.9×); Fwd P/E of 8.0× (cheaper than the peer median of 17.5×); P/B of 2.8× (cheaper than the peer median of 7.8×); P/S of 2.9× (cheaper than the peer median of 6.2×); EV/EBITDA of 8.2× (cheaper than the peer median of 18.5×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. JAZZ shows a price-to-book (P/B) of 2.80 and book value of $74.10 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. JAZZ is in a mixed trend, trading -22.0% from its 52-week high. Over the past year the stock is +55.9%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
JAZZ vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | JAZZ | Peer median | Read |
|---|---|---|---|
| P/E | 14.2× | 41.9× | cheaper than |
| Fwd P/E | 8.0× | 17.5× | cheaper than |
| P/B | 2.8× | 7.8× | cheaper than |
| P/S | 2.9× | 6.2× | cheaper than |
| EV/EBITDA | 8.2× | 18.5× | cheaper than |
What does Jazz Pharmaceuticals plc do?
What does it do?
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It operates in the Biotechnology industry (Healthcare sector), headquartered in Ireland. The company employs roughly 2,890 people.
How does it make money?
The business turns $4.3B in annual revenue into profit. Out of every $100 of sales, about $27 is left as operating profit (operating margin of 26.9%), after a 91% gross margin on the products/services it sells. After all costs, taxes and interest, 20.4% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: carries modest debt (0.9× equity), comfortably covers its short-term bills (1.8× current ratio), and is currently profitable.
Who at JAZZ filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| GALA RENEE D | Director, President & CEO | Open-market sale | $472,800.00 | Form 4 for GALA RENEE D (opens sec.gov in a new tab) | |
| COZADD BRUCE C | Director | Open-market sale | $1,381,980.00 | Form 4 for COZADD BRUCE C (opens sec.gov in a new tab) | |
| Patil Neena M | EVP & Chief Legal Officer | Open-market sale | $289,128.00 | Form 4 for Patil Neena M (opens sec.gov in a new tab) | |
| GALA RENEE D | President & CEO | Shares withheld (tax) | $485,475.27 | Form 4 for GALA RENEE D (opens sec.gov in a new tab) | |
| GALA RENEE D | President & CEO | Open-market sale | $486,060.00 | Form 4 for GALA RENEE D (opens sec.gov in a new tab) | |
| Henderson Mary Elizabeth | SVP, Technical Operations | Shares withheld (tax) | $343,158.22 | Form 4 for Henderson Mary Elizabeth (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.